Efficacy of bovine viral diarrhea modified-live virus vaccine to provide fetal protection for BVDV type 1 and 2 virus in cattle

Abstract

Effective control of bovine viral diarrhea virus (BVDV) requires that vaccination provide a high level of protection not only to the dam, but also to the calf in utero, preventing fetal infection and the development of persistently infected (PI) calves. The objective of this study was to determine if primiparous cows vaccinated with a BVDV modified-live virus vaccine (Titanium® 5 L5 HB, Elanco Animal Health, Greenfield, IN, USA) were protected from fetal infections and the development of PI calves following exposure to virulent non-cytopathic type 1 and 2 BVDV.